← Back to Screener
HeartSciences Inc. Common Stock (HSCS)
Price$2.05
Favorite Metrics
Price vs S&P 500 (26W)-47.15%
Price vs S&P 500 (4W)-25.18%
Market Capitalization$6.85M
All Metrics
Book Value / Share (Quarterly)$0.83
P/TBV (Annual)1.06x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-32.90%
Cash Flow / Share (Quarterly)$-2.32
Price vs S&P 500 (YTD)-34.56%
Gross Margin (TTM)57.90%
Net Profit Margin (TTM)-74972.20%
EPS (TTM)$-5.01
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-5.01
Revenue Growth (5Y)-41.63%
EPS (Annual)$-9.34
ROI (Annual)-318.00%
Gross Margin (Annual)56.78%
Net Profit Margin (5Y Avg)-80463.65%
Cash / Share (Quarterly)$1.07
ROA (Last FY)-207.56%
Revenue Growth TTM (YoY)-41.02%
EBITD / Share (TTM)$-3.73
Operating Margin (TTM)-67680.74%
Cash Flow / Share (Annual)$-6.65
P/B Ratio2.58x
P/B Ratio (Quarterly)3.83x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)804.04x
Net Interest Coverage (TTM)-16.51x
ROA (TTM)-140.19%
EPS Incl Extra (Annual)$-9.34
Current Ratio (Annual)0.59x
Quick Ratio (Quarterly)1.00x
3-Month Avg Trading Volume0.03M
52-Week Price Return-29.74%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.17
P/S Ratio (Annual)1573.97x
Asset Turnover (Annual)0.00x
52-Week High$6.47
Operating Margin (5Y Avg)-76697.50%
EPS Excl Extra (Annual)$-9.34
CapEx CAGR (5Y)21.50%
26-Week Price Return-38.40%
Quick Ratio (Annual)0.39x
13-Week Price Return-31.97%
Total Debt / Equity (Annual)12.43x
Current Ratio (Quarterly)1.19x
Enterprise Value$6.971
Revenue / Share Growth (5Y)-10.48%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.00x
Pretax Margin (Annual)-201499.54%
Cash / Share (Annual)$0.98
3-Month Return Std Dev60.68%
Gross Margin (5Y Avg)54.72%
Net Income / Employee (TTM)$-1
ROE (Last FY)-4272.18%
Net Interest Coverage (Annual)-11.03x
EPS Basic Excl Extra (Annual)$-9.34
Receivables Turnover (TTM)2.48x
Total Debt / Equity (Quarterly)1.33x
EPS Incl Extra (TTM)$-5.01
Receivables Turnover (Annual)4.44x
ROI (TTM)-185.53%
P/S Ratio (TTM)789.71x
Pretax Margin (5Y Avg)-80463.65%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.47
Price vs S&P 500 (52W)-64.84%
Year-to-Date Return-30.42%
5-Day Price Return8.04%
EPS Normalized (Annual)$-9.34
ROA (5Y Avg)-165.73%
Net Profit Margin (Annual)-201499.54%
Month-to-Date Return-14.48%
Cash Flow / Share (TTM)$-0.67
EBITD / Share (Annual)$-8.77
Operating Margin (Annual)-192013.10%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$-5.01
P/TBV (Quarterly)18.91x
P/B Ratio (Annual)18.47x
Inventory Turnover (TTM)0.01x
Pretax Margin (TTM)-74972.20%
Book Value / Share (Annual)$0.18
Price vs S&P 500 (13W)-34.83%
Beta2.20x
Revenue / Share (TTM)$0.00
ROE (TTM)-333.38%
52-Week Low$1.89
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Orthopedic & Prosthetic Devices(25)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
HSCSHeartSciences Inc. Common Stock | 789.71x | -41.63% | 57.90% | -67680.74% | $2.05 |
ISRGIntuitive Surgical Inc. | 16.54x | 18.22% | 66.00% | 29.27% | $465.60 |
EWEdwards Lifesciences Corp | 7.77x | 6.70% | 78.01% | 18.41% | $81.44 |
STESTERIS plc | 3.81x | 12.49% | 44.11% | 17.03% | $226.41 |
ZBHZimmer Biomet Holdings, Inc. | 2.31x | 3.22% | 69.71% | 13.34% | $95.48 |
ALGNAlign Technology Inc | 3.41x | 10.30% | 68.27% | 13.53% | $191.66 |
SNNSmith & Nephew plc | 2.37x | 6.21% | 68.01% | 12.88% | $34.21 |
MSAMine Safety Incorporated | 3.60x | 6.82% | 46.46% | 19.83% | $173.50 |
ESTAEstablishment Labs Holdings Inc. | 9.30x | 20.04% | 69.32% | -18.48% | $66.93 |
ENOVEnovis Corporation | 0.68x | -6.05% | 58.16% | -50.09% | $26.27 |
CDRECadre Holdings, Inc. | 2.19x | 8.57% | 42.54% | 11.04% | $30.51 |
About
HeartSciences Inc develops artificial intelligence-powered ECG solutions for earlier detection of heart disease in clinical and point-of-care settings. The company's technology is delivered through MyoVista Insights, a cloud platform compatible with existing ECG devices, and MyoVista wavECG, a standalone device. By enhancing the diagnostic value of standard ECGs, HeartSciences addresses the significant need for improved cardiac screening in frontline healthcare environments.